Elyse Seltzer
PsiOxus Therapeutics (United Kingdom)(GB)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Urological Disorders and Treatments, Urinary and Genital Oncology Studies, Antimicrobial Resistance in Staphylococcus, Vector-borne infectious diseases
Most-Cited Works
- → Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections(2005)309 cited
- → Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens(2005)293 cited
- → Once-Weekly Dalbavancin versus Standard-of-Care Antimicrobial Regimens for Treatment of Skin and Soft-Tissue Infections(2003)233 cited
- → Long-term Outcomes of Persons With Lyme Disease(2000)205 cited
- → Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial(2019)140 cited
- → Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial(2020)131 cited
- → Misdiagnosis of Lyme disease: when not to order serologic tests(1996)76 cited
- → Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial(2019)75 cited
- → Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment(2009)74 cited
- → Pharmacokinetics of dalbavancin in plasma and skin blister fluid(2007)64 cited